en · de · es · fr · pt
ipamorelin-notes.peptides8425.com › Guide › Background And Receptor Mechanism — 2026 Update

Background And Receptor Mechanism — 2026 Update

By Editorial Desk · published 2025-11-07 · last reviewed 2025-12-14 · Guide

pentapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-12-14 and is reviewed periodically as new material appears.

Background And Receptor Mechanism

Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.

Handling Storage And Analytical Control

In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.

Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.

Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.

Ipamorelin at a glance

PropertyValueNotes
Chemical classSynthetic pentapeptideGrowth hormone secretagogue family
Molecular massApproximately 711.9 DaFree base, calculated value
Receptor targetGHS-R1a, the ghrelin receptorAgonist activity reported
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2C-terminal amide
Reported selectivityLittle change in ACTH, cortisol, prolactinBased mainly on animal data

Ipamorelin Background and Receptor Selectivity

Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.

Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.

Related pages on this site

Background and Receptor Selectivity

Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.

Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.

背景与分子特征

在 GHS 家族中,早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放,并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性,对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同,而完整的分子解释仍有待补充。需要区分的是,选择性是研究观察中的相对程度,并非绝对界限。

从用途定位看,ipamorelin 目前主要以研究用肽的身份被讨论,未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用,不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小,因此对其效应强度与一致性的描述应保持谨慎。

Ipamorelin 是一种合成五肽,序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2,分子式 C38H49N9O5,游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素(GHS)家族,作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道,设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。

Background and Structural Identity

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Supporting material

Phenelzine, sold under the brand name Nardil among others, is a non-selective and irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine family which is primarily used as an antidepressant and anxiolytic to treat depression and anxiety. Along with tranylcypromine and isocarboxazid, phenelzine is one of the few non-selective and irreversible MAOIs still in widespread clinical use.

The discovery of the backdoor pathway to DHT biosynthesis in tammar wallaby pouch young prompted research into identifying and characterizing similar pathways in humans, leading to a better understanding of the regulation, metabolism, and therapeutic targeting of androgen biosynthesis in human health and diseases related to excessive or insufficient androgen biosynthesis when the classical androgen pathway could not fully explain the observed conditions in patients. Over the following two decades, several other distinct pathways have been discovered: the pathways that lead to the synthesis of 11-oxygenated androgens. Below is a brief selection of key events in the history of androgen backdoor pathway research:

A blood smear, peripheral blood smear or blood film is a thin layer of blood smeared on a glass microscope slide and then stained in such a way as to allow the various blood cells to be examined microscopically . Blood smears are examined in the investigation of hematological (blood) disorders and are routinely employed to look for blood parasites, such as those of malaria and filariasis.

== History == Octreotide acetate was approved for use in the United States in 1988. In January 2020, approval of octreotide acetate in the United States was granted to Sun Pharmaceutical under the brand name Bynfezia Pen for the treatment of:

The tables below contain a sample list of benzodiazepines and benzodiazepine analogs that are commonly prescribed, with their basic pharmacological characteristics, such as half-life and equivalent doses to other benzodiazepines, also listed, along with their trade names and primary uses. The elimination half-life is how long it takes for half of the drug to be eliminated by the body. "Time to peak" refers to when maximum levels of the drug in the blood occur after a given dose. Benzodiazepines generally share the same pharmacological properties, such as anxiolytic, sedative, hypnotic, skeletal muscle relaxant, amnesic, and anticonvulsant effects. Variation in potency of certain effects may exist amongst individual benzodiazepines. Some benzodiazepines produce active metabolites. Active metabolites are produced when a person's body metabolizes the drug into compounds that share a similar pharmacological profile to the parent compound and thus are relevant when calculating how long the pharmacological effects of a drug will last. Long-acting benzodiazepines with long-acting active metabolites, such as diazepam and chlordiazepoxide, are often prescribed for benzodiazepine or alcohol withdrawal as well as for anxiety if constant dose levels are required throughout the day. Shorter-acting benzodiazepines are often preferred for insomnia due to their lesser hangover effect. It is fairly important to note that elimination half-life of diazepam and chlordiazepoxide, as well as other long half-life benzodiazepines, is twice as long in the elderly compared to younger individuals.

Sources: en.wikipedia.org

Supporting material

Avoiding smoking Cutting down on fats to help reduce the amount of plaque buildup Eating a healthy diet, including plenty of fruits and vegetables Limiting sodium in the diet, thereby reducing blood pressure Exercising regularly Moderating intake of alcohol, stimulants, sympathomimetics, etc. Maintaining a healthy weight In addition, it is important to control any underlying medical conditions that may increase the risk of stroke or TIA, including:

=== pH buffering === The pH of the mobile phase can change the retention and selectivity of analytes. For samples containing solutes with ionized functional groups, such as amines, carboxyls, phosphates, phosphonates, sulfates, and sulfonates, the ionization of these groups can be controlled by controlling the pH of the mobile phase. The pH of the mobile phase can be controlled by mobile phase buffers. In general, molecules with acidic function groups are increasingly ionized under more alkaline environments, and thus its retention time would decrease. Conversely, under more acidic environments, its retention time would increase. Conversely for molecules with alkaline function groups. For example, carboxylic groups in solutes become increasingly negatively charged as the pH of the mobile phase rises above their pKa, hence the whole molecule becomes more polar and less retained on the a-polar stationary phase. In this case, raising the pH of the phase mobile above 4–5 = pH (which is the typical pKa range for carboxylic groups) increases their ionization, hence decreases their retention. Similarly, molecules with amine groups usually have pKa around 8. However, since silica gel is not stable in alkaline environments, the mobile phase typically does not have pH above 8. Therefore, control over the retention of amines is limited when the stationary phase is based on silica gel. The choice of buffer type is an important factor in RP-LC method development, as it can affect the retention, selectivity, and resolution of the analytes of interest.

== Applications == Lysine carboxypeptidase is found within the plasma and is used to inactivate certain proteins; this functions to protect the body from potent molecules that may escape from tissues. The most well-studied protein that is inactivated by this enzyme is bradykinin (along with other kinins such as kallidin) which contributes to inflammation and blood pressure regulation. However, the primary way bradykinin is degraded is by angiotensin I converting enzyme (ACE). Lysine carboxypeptidase is still important nonetheless, especially if a patient is receiving ACE inhibitors to treat a condition. Kinins are most often autocrine or paracrine hormones and are thus often restricted in location. If too much of the hormone escapes into the blood and levels rise too high, this can have harmful effects on the body. Lysine carboxypeptidase prevents this from happening. This enzyme has also proven to be important in inactivating anaphylatoxins which are inflammation-inducing proteins used in immune responses. Similarly to kinins, harmful effects can occur if too much of these proteins accumulate in the blood. Other molecules that this enzyme is involved in modifying, and consequently regulating, include creatine kinase, hemoglobin, stromal cell-derived factor-1α (SDF-1α), plasminogen receptors, and enkephalins. The enzymatic interaction with creatine kinase releases one lysine from each of two subunits and modifies its function. With hemoglobin, it speeds up the dissociation of the tetramer into dimers and increases its oxygen affinity.

These isoenzymes include MM, MB, and BB, which all carry out the same function given different amino acid sequences. The functions of these isoenzymes are to convert creatine, using ATP, into phosphocreatine expelling ADP. Mini columns were filled with DEAE-Sephadex A-50 and further eluted with tris- buffer sodium chloride at various concentrations (each concentration was chosen advantageously to manipulate elution). Human tissue extract was inserted in columns for separation. All fractions were analyzed to see total CK activity and it was found that each source of CK isoenzymes had characteristic isoenzymes found within. Firstly, CK- MM was eluted, then CK-MB, followed by CK-BB. Therefore, the isoenzymes found in each sample could be used to identify the source, as they were tissue specific. Using the information from results, correlation could be made about the diagnosis of patients and the kind of CK isoenzymes found in most abundant activity. From the finding, about 35 out of 71 patients studied suffered from heart attack (myocardial infarction) also contained an abundant amount of the CK-MM and CK-MB isoenzymes. Findings further show that many other diagnosis including renal failure, cerebrovascular disease, and pulmonary disease were only found to have the CK-MM isoenzyme and no other isoenzyme. The results from this study indicate correlations between various diseases and the CK isoenzymes found which confirms previous test results using various techniques.

A gel refers to the semi-solid, 3-dimensional matrix formed from an interspersed system of colloidal particles or the permeation of a solvent into an entwined polymer chain network. Pharmaceutical gels are formed by adding a gelator (gelling agent) to the solvent and active ingredient mixture. Gelators used in gel formulation can be small molecules with low molecular weight or polymers (synthetic, semi-synthetic or natural). The solvent that is used as a dispersion medium can be aqueous, organic, inorganic, or a system of different solvents. Topical gels are used as a contact or transport medium for active drugs to act on or through the skin. The active drug molecules are entwined into the 3D mesh of the gel and delivered to the site of action.

Sources: en.wikipedia.org

Notes from published material

== Clinical significance == Disorders of capillary formation as a developmental defect or acquired disorder are a feature in many common and serious disorders. Within a wide range of cellular factors and cytokines, issues with normal genetic expression and bioactivity of the vascular growth and permeability factor vascular endothelial growth factor (VEGF) appear to play a major role in many of the disorders. Cellular factors include reduced number and function of bone-marrow derived endothelial progenitor cells. and reduced ability of those cells to form blood vessels.

The structure had an inside volume or hollow cavity encased by triangular faces, similar to a pyramid. This close-faced cage was designed to potentially encapsulate other materials such as proteins and metal nanoparticles.===Virus assembly=== During assembly of the bacteriophage (phage) T4 virion, the morphogenetic proteins encoded by the phage genes interact with each other in a characteristic sequence. Maintaining an appropriate balance in the amounts of each of these proteins produced during viral infection appears to be critical for normal phage T4 morphogenesis. Phage T4 encoded proteins that determine virion structure include major structural components, minor structural components and non-structural proteins that catalyze specific steps in the morphogenesis sequence

The Weird Sisters in Shakespeare's Macbeth used the fur of a bat in their brew. In Western culture, the bat is often a symbol of the night and its foreboding nature. The bat is a primary animal associated with fictional characters of the night, both villainous vampires, such as Count Dracula and the earlier Varney the Vampire, and heroes, such as the DC Comics character Batman. The bat is sometimes used as a heraldic symbol in many European countries, including France, Belgium, Germany, Spain and the UK. They have also been used as symbols in the militaries of the UK, US and Israel. Three US states have an official state bat. Texas and Oklahoma are represented by the Mexican free-tailed bat, while Virginia is represented by the Virginia big-eared bat (Corynorhinus townsendii virginianus).

== Book chapters == 1. Richoz O, Hafezi F Modifications for Thin Corneas, in Corneal collagen cross-linking, Randleman B, Hafezi F, Editors. 2013, Slack Inc.: Thorofare, NJ, USA. 51–55. 2. Hafezi F, Mavrakanas N Corneal Collagen Cross-Linking for Postoperative Corneal Ectasia, in Corneal collagen cross-linking, Randleman B, Hafezi F, Editors. 2013, Slack Inc.: Thorofare, NJ, USA. 75–81. 3. Pajic B, Latinovic S, Hafezi F, Pajic-Eggspuehler B, Mrochen M, Fankhauser F Lamellar corneal resection with LDV Crystal line femtosecond laser after penetrating keratoplasty, in Femtosecond laser technology, Gark A, Editor. 2012, Jaypee Brothers: Mumbai. 4. Pajic B, Hafezi F, Pajic-Eggspuehler B, Mrochen M, Mueller J, Pajic D, Fankhauser F Applanation-free femtosecond laser processing of the cornea, in Femtosecond laser technology, Gark A, Editor. 2012, Jaypee Brothers: Mumbai. 5. Iseli HP, Hafezi F, Mrochen M, Seiler T Estado actual de la reticulación del colágeno corneal, in Técnicas de modelado corneal: desde la ortoqueratologia hasta el cross-linking, Cezón Prieto J, Editor. 2009, Sociedad Española de Cirurgia Ocular Implanto-Refractiva: Madrid. 381–86. 6. Hafezi F, Iseli HP, Seiler T Automated anterior lamellar keratoplasty for the management of complications in refractive surgery, in Surgical techniques in anterior and posterior lamellar corneal surgery, John T, Editor. 2005, Slack Inc.: New York. (in press). 7.

Berkelium is a soft, silvery-white, radioactive actinide metal. In the periodic table, it is located to the right of the actinide curium, to the left of the actinide californium and below the lanthanide terbium with which it shares many similarities in physical and chemical properties. Its density of 14.78 g/cm3 lies between those of curium (13.52 g/cm3) and californium (15.1 g/cm3), as does its melting point of 986 °C, below that of curium (1340 °C) but higher than that of californium (900 °C). Berkelium is relatively soft and has one of the lowest bulk moduli among the actinides, at about 20 GPa (2×1010 Pa). Berkelium(III) ions shows two sharp fluorescence peaks at 652 nanometers (red light) and 742 nanometers (deep red – near-infrared) due to internal transitions at the f-electron shell. The relative intensity of these peaks depends on the excitation power and temperature of the sample. This emission can be observed, for example, after dispersing berkelium ions in a silicate glass, by melting the glass in presence of berkelium oxide or halide. Between 70 K and room temperature, berkelium behaves as a Curie–Weiss paramagnetic material with an effective magnetic moment of 9.69 Bohr magnetons (μB) and a Curie temperature of 101 K. This magnetic moment is almost equal to the theoretical value of 9.72 μB calculated within the simple atomic L-S coupling model. Upon cooling to about 34 K, berkelium undergoes a transition to an antiferromagnetic state.

Sources: en.wikipedia.org

Frequently asked questions

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.

How does ipamorelin differ from ghrelin?

Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.

Are the effects of ipamorelin well established in humans?

Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.

How is ipamorelin purity measured?

Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.

Network